Certara, Inc. (CERT) is a leading global biosimulation company that aims to advance the health outcomes of patients by using modeling, simulation, and data science. The firm is publicly listed on Nasdaq under the ticker symbol 'CERT.'
Founded in 2008 and headquartered in Princeton, New Jersey, Certara provides its innovative technologies and services to over 1,600 companies, including all top 20 global pharmaceutical companies, hundreds of biotech and specialty pharma firms, regulatory agencies such as the FDA, NIH, and EMA, and academic institutions. The company's tools are used in the development of small molecules, biologics, cell and gene therapies, and consumer health products.
Certara operates under a unique business model. By using a biosimulation approach to drug development, it leverages the use of mathematical models to predict how drugs might behave in different scenarios. This reduces the need for extensive and costly clinical trials and increases the efficiency of the drug discovery process.
At the heart of Certara's offerings is its proprietary flagship software, Simcyp, which is widely recognized for its excellent pharmacokinetic and pharmacodynamic modeling capabilities. Simcyp allows researchers to simulate drug interactions in virtual patient populations and yield data that helps to inform dosing decisions and strategies.
Beyond drug development, Certara also provides strategic regulatory science consulting services to assist clients in obtaining regulatory approval. The firm's regulatory team is comprised of former FDA and EMA reviewers, offering unparalleled insights into global drug regulatory processes.
With over 700 global employees, Certara continues to expand its operations worldwide to better meet the needs of its customers. In December 2020, the company went public through an Initial Public Offering (IPO) on the Nasdaq Global Select Market.
Since its inception, Certara has become a key player in the biosimulation market. Through its unwavering commitment to innovation and application of learning from real-world evidence, this trailblazing firm continues to accelerate the pace of drug discovery and development, bringing safer, more effective medicines to patients sooner.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Certara reported a 4% year-over-year revenue increase in Q3 2026, reaching $94.9 million, primarily driven by 11% growth in software revenue. The company also saw a 6% increase in adjusted EBITDA to $30.2 million, attributed to operational efficiencies. Certara is focusing on integrating AI, expanding cloud capabilities, and targeting growth in biotech, mid-sized pharma, and the APAC region, while narrowing its full-year revenue growth guidance to 2-3%.
Argus has raised its target price for Certara Inc. (CERT) to $9.00. The company, which trades under the symbol CERT in the Healthcare sector, is currently priced at $11.02. Certara Inc. utilizes biosimulation software and technology to expedite drug discovery and development processes.
Certara (CERT) shares have rallied 73% despite modest revenue and profit growth forecasts, driven by expectations of a turnaround in software momentum and new leadership. The upcoming third-quarter report is crucial to demonstrate whether this story is moving from promise to proof, particularly concerning the performance of its services segment and improved margins. The market is looking for solid bookings growth in software and signs that the recent commercial restructuring in services is effectively converting its pipeline.
This article examines the individual drivers behind the early trading gains of AngloGold Ashanti (NYSE:AU), Ramaco Resources (NASDAQ:METC), SailPoint (NASDAQ:SAIL), and Certara (NASDAQ:CERT). While no immediate news from October 23-26, 2026, was found for any of the four, their respective price movements are linked to recent financial reports and operational updates. The article suggests that the broad market movement may be contributing to the synchronized early trading gains across these diverse companies.
This article from Yahoo Finance provides the options chain for Certara, Inc. (CERT). It displays real-time price data, with the stock trading at $9.79, up 3.54% at market close on October 20th. The options data, delayed by 15 minutes, shows no available calls or puts.
TD Cowen maintained a 'Buy' rating for Certara (CERT) and raised its price target from $9.00 to $11.00, reflecting optimism about the company's growth potential. GuruFocus assesses Certara as 20.4% undervalued with a GF Value™ of $12.18, despite being unprofitable, and notes a GF Score™ of 73/100 indicating solid overall performance. Guru activity shows a positive sentiment, with 7 gurus holding positions and no insider selling in the last three months.